Formycon AG has acquired rights to two of Athos’ biosimilar candidates as part of a long-term strategic partnership between the two companies, in exchange for a consideration of approximately €650m ($725m).
Formycon Strengthens Biosimilars Portfolio With Athos Assets
Deal Will Be Paid For With A Consideration Worth Approximately €650m
Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.
More from Deals
More from Business
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.